Oppenheimer Lowers Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $15.00
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) had its price target decreased by equities researchers at Oppenheimer from $20.00 to $15.00 in a research report issued on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Oppenheimer’s target price suggests a potential upside of 218.47% from the company’s current price. YMAB has […]
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) had its price target decreased by equities researchers at Oppenheimer from $20.00 to $15.00 in a research report issued on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Oppenheimer’s target price suggests a potential upside of 218.47% from the company’s current price. YMAB has […]
